Determinants of tofacitinib discontinuation in adult patients with rheumatoid arthritis during long-term extension studies up to 9.5 years.
Jeffrey R CurtisJürgen WollenhauptSander W TasKaterina ChatzidionysiouLisy WangKevin RobertsVassilis TsekourasPublished in: Rheumatology advances in practice (2024)
ClinicalTrials.gov (http://clinicaltrials.gov): NCT00413699 and NCT00661661.